QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NASDAQ:NXTC

NextCure Stock Forecast, Price & News

$7.87
+0.14 (+1.81 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.67
$7.95
50-Day Range
$6.74
$9.10
52-Week Range
$6.69
$14.40
Volume
524,159 shs
Average Volume
251,381 shs
Market Capitalization
$217.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.35
30 days | 90 days | 365 days | Advanced Chart
Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.


NextCure logo

About NextCure

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NXTC
Employees
90
Year Founded
N/A

Sales & Book Value

Annual Sales
$22.38 million
Book Value
$10.66 per share

Profitability

Net Income
$-36.60 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
24,823,000
Market Cap
$217.31 million
Next Earnings Date
11/4/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

613th out of 1,372 stocks

Pharmaceutical Preparations Industry

292nd out of 669 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












NextCure (NASDAQ:NXTC) Frequently Asked Questions

Is NextCure a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NextCure stock.
View analyst ratings for NextCure
or view top-rated stocks.

What stocks does MarketBeat like better than NextCure?

Wall Street analysts have given NextCure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NextCure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NextCure's next earnings date?

NextCure is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for NextCure
.

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) posted its quarterly earnings data on Thursday, August, 5th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.04.
View NextCure's earnings history
.

How has NextCure's stock been impacted by COVID-19 (Coronavirus)?

NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NXTC shares have decreased by 79.4% and is now trading at $7.87.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NXTC?

5 brokers have issued 1 year price targets for NextCure's stock. Their forecasts range from $10.00 to $21.00. On average, they expect NextCure's stock price to reach $17.20 in the next year. This suggests a possible upside of 118.6% from the stock's current price.
View analysts' price targets for NextCure
or view top-rated stocks among Wall Street analysts.

Who are NextCure's key executives?

NextCure's management team includes the following people:
  • Michael S. Richman, President, Chief Executive Officer & Director
  • Timothy Mayer, Chief Operating Officer
  • Steven P. Cobourn, Chief Financial Officer
  • Solomon Langermann, Chief Scientific Officer
  • Linda N. Liu, Senior Vice President-Research

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), OrganiGram (OGI), (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Who are NextCure's major shareholders?

NextCure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Marquette Asset Management LLC (0.05%).
View institutional ownership trends for NextCure
.

Which major investors are buying NextCure stock?

NXTC stock was acquired by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC.
View insider buying and selling activity for NextCure
or or view top insider-buying stocks.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $7.87.

How much money does NextCure make?

NextCure has a market capitalization of $217.31 million and generates $22.38 million in revenue each year. The company earns $-36.60 million in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does NextCure have?

NextCure employs 90 workers across the globe.

What is NextCure's official website?

The official website for NextCure is www.nextcure.com.

Where are NextCure's headquarters?

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at (240) 399-4900 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.